Latest Antigen Express Inc. Stories
WORCESTER, Mass. and TORONTO, Jan. 17, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that a detailed interview conducted at the BioTech Showcase 2012 during last week's JPMorgan Healthcare Conference in San Francisco with Dr. Eric von Hofe, Ph.D., President of Generex subsidiary Antigen Express, Inc., regarding the Antigen Express breast cancer vaccine, is available on the Stock News Now website (www.stocknewsnow.com) and on the Generex...
WORCESTER, Mass. and TORONTO, Jan. 4, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today that representatives of the Company's wholly-owned subsidiary, Antigen Express, Inc., will be in attendance at the 2012 JPMorgan Healthcare Conference in San Francisco from January 8 through 13. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b ) Representatives of Antigen Express will be available over the course of the conference to meet with...
WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37. Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in...
WORCESTER, Mass. and TORONTO, Dec. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that the previously announced Bloomberg Television segment on the Antigen Express breast cancer vaccine aired yesterday evening (December 20, 2011). The segment can be viewed on the Company's website at www.generex.com or on the Bloomberg website at http://www.bloomberg.com/video/83137924/. (Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)...
WORCESTER, Mass. and TORONTO, Dec. 20, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that the Bloomberg Television segment on the Antigen Express breast cancer vaccine did not air yesterday as originally scheduled (and announced in Bloomberg Television's December 16, 2011 promotional spot). The Company will provide a further update once representatives of Bloomberg Television advise as to a rescheduled air date and time. (Logo:...
WORCESTER, Mass. and TORONTO, Dec. 19, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT.OB) today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The segment is scheduled to air at 6 pm EST (3 pm PST) today, Monday, December 19, 2011 (see promo at http://i879.photobucket.com/albums/ab357/tc2000chartreader/72389a92.mp4. It is...
WORCESTER, Mass. and TORONTO, Dec. 14, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that Bloomberg Television will air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. The story, expected to air December 19, 2011, will cover the Company's novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37), which is the subject of an ongoing Phase 2 clinical study in...
WORCESTER, Mass. and TORONTO, Dec. 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) today announced that positive interim Phase 2 clinical data from its ongoing study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients were presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The AE37 vaccine is being developed by its wholly-owned subsidiary,...
WORCESTER, Mass. and TORONTO, Nov. 21, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) (www.generex.com) announced today that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will present new Phase 2 clinical data from its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas on December...
WORCESTER, Mass. and TORONTO, Oct. 24, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) announced today that the Company is planning an investor update conference call for late November. The purpose of the call is to provide investors with an update on (i) the status of the Company's efforts in respect of the previously announced spinout of its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), (ii) financing...
